Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kiovig versus Gammagard in CIDP
NL-OMON31412Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Gammagard with Kiovig (2 arms). Primary endpoint: Efficacy by Overall Disability Sum Score. Started Dec 2007; status: active, not recruiting.
02
Drugs
kiovigpolyvalent human immunoglobulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON31412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31412.